AMENDMENTS TO THE CLAIMS

1. (Currently amended) A bicyclo derivative represented by the following formula (1):

$$\begin{array}{c|c}
R^1 & & \\
& & \\
N & \\
H & O \\
\end{array}$$
(1)

wherein R¹ is Mecarboxyl group; X is CH₂, CHF, CF₂ or CHOH; and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

2-5. (Cancelled)

6. (Previously presented) A pharmaceutical product containing as an active ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.

7. (Cancelled)

- 8. (Withdrawn) A method for treating a mammal having a disease involving DPP-IV, which comprises administering a therapeutically effective amount of the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.
- 9. (Withdrawn) The method according to claim 8, wherein the disease involving DPP-IV is diabetes or associated diabetic complication.
- 10. (New) The bicyclo derivative according to claim 1, wherein the compound represented by the formula (1) is (2S,4S)-1-[[N-(4-carboxybicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile or a pharmaceutically acceptable salt thereof.